2.310USD+2.21%Mkt Cap: 144.55M USDP/E: —Last update: 2026-05-26
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR m…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap144.55M USD
Enterprise Value79.10M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-22.40M USD
Revenue/Share—
Last Price2.310 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees14
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-8.39
PEG—
EV/EBITDA-3.90
EV/Revenue—
P/S—
P/B2.35
EPS (TTM)-0.21
EPS (Forward)-0.26
52W Range
0.270084% of range2.700
52W High2.700 USD
52W Low0.2700 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-78.32%
ROA-70.24%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-22.75M USD
CapEx (TTM)48.00K USD
FCF Margin—
FCF Yield-8.68%
Net Debt-60.63M USD
Net Debt/EBITDA2.99
Balance Sheet
Debt/Equity0.03
Current Ratio18.62
Quick Ratio18.33
Book Value/Sh0.9410 USD
Cash/Share0.9700 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)6.375 USD
Target Range1.000 USD – 12.00 USD
# Analysts8
Ownership
Shares Out.63.23M
Float31.50M
Insiders16.41%
Institutions64.23%
Short Interest
Short Ratio7.2d
Short % Float5.15%
Short % Out.4.45%
Shares Short2.81M
Short (prev mo.)2.73M
Technical
SMA 502.069 (+11.6%)
SMA 2001.551 (+48.9%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)330.35K
Avg Vol (10d)309.98K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—